← Leaderboards
Scott H Wadler
Yeshiva University
$927,558
Attributed
$927,558
Total exposure
14
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $223K · FY2005–06$250K$187.5K$125K$62.5K$0
'05
'06
Funding mix
By agency
NIH$927,558 · 14
By mechanism
U10$412,889 · 2
M01$334,377 · 8
U01$180,292 · 1
P30$0 · 3
Top collaborators
No co-investigators on record.
Most similar at Yeshiva University
Same institution · by research overlap
- Howard D Strickler$24,187,784
- Anna S Kadish$724,516
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchNeoplasm /Cancer ImmunotherapyAntineoplasticsNeoplasm /Cancer VaccineBiomedical FacilityNeoplasm /Cancer ChemotherapyClinical TrialsCombination ChemotherapyCombination Cancer TherapyCooperative StudyGastrointestinal NeoplasmsCancer PreventionNeoplasm /Cancer Radiation TherapyBreast NeoplasmsNeoplasm /Cancer SurgeryBone Marrow TransplantationNeoplasm /Cancer GeneticsLymphomaDrug Screening /EvaluationLeukemiaMelanomaNeoplasm /Cancer Pharmacology
Grant awards (26)
PHASE II STUDY PS341 ALONE OR COMB W/ IRINOTECAN IN PATIENTS W/ ADENOCARCINOMA$28,359
M01 · FY2006 · RR · contact PI
PHII TRIAPINE W/ GEMCITABINE ADENOCARCINOMA OF BILIARY DUCTS AND GALL BLADDER$28,359
M01 · FY2006 · RR · contact PI
PHASE II STUDY BEVACIZUMAK, CETUXIMAB, IRINOTECAN IN COLORECTAL CANCER$12,154
M01 · FY2006 · RR · contact PI
A PHASE I/II STUDY OF GENASENSE (G3139) IN COMBINATION WITH CISPLATIN AND FLUORO$9,723
M01 · FY2006 · RR · contact PI
PHASE II STUDY PS341 ALONE OR COMB W/ IRINOTECAN IN PATIENTS W/ ADENOCARCINOMA$94,014
M01 · FY2005 · RR
PHASE II STUDY BEVACIZUMAK, CETUXIMAB, IRINOTECAN IN COLORECTAL CANCER$65,591
M01 · FY2005 · RR
PHASE II STUDY OF BEVACIZUMAB (RHUMAB-VEGF) IN HEPATOCELLULAR CANCER$37,896
M01 · FY2005 · RR
A PHASE I/II STUDY OF GENASENSE (G3139) IN COMBINATION WITH CISPLATIN AND FLUORO$16,033
M01 · FY2005 · RR
PHII TRIAPINE W/ GEMCITABINE ADENOCARCINOMA OF BILIARY DUCTS AND GALL BLADDER$9,474
M01 · FY2005 · RR
Phase II Study of Bevacizumab (RhuMAB-VEGF) in Hepatocellular Cancer$14,388
M01 · FY2004 · RR
Ph.II triapine w/ gemcitabine adenocarcinoma of biliary ducts and gall bladder$11,192
M01 · FY2004 · RR
Phase II Study PS341 Alone or Comb. w/ Irinotecan in Patients w/ Adenocarcinoma$7,194
M01 · FY2004 · RR
CANCER AND LEUKEMIA GROUP B$54,665
U10 · FY2002 · CA
CORE--PROTOCOL SPECIFIC RESEARCH SUPPORT$0
P30 · FY2002 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0
P30 · FY2002 · CA
CORE--CENTRALIZED PROTOCOL AND DATA MANAGEMENT UNIT$0
P30 · FY2002 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP$164,396
U10 · FY2001 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP$36,000
U10 · FY2001 · CA
CORE--CENTRALIZED PROTOCOL AND DATA MANAGEMENT UNIT$0
P30 · FY2001 · CA
CORE--PROTOCOL SPECIFIC RESEARCH SUPPORT$0
P30 · FY2001 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0
P30 · FY2001 · CA
PHASE II STUDY OF VACCINE FOR ADVANCED PROSTATE CANCER$0
M01 · FY2001 · RR
GYNECOLOGIC MALIGNANCIES--NOVEL PHASE II AGENTS$158,199
U01 · FY2000 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP$157,828
U10 · FY2000 · CA
GYNECOLOGIC MALIGNANCIES--NOVEL PHASE II AGENTS$22,093
U01 · FY2000 · CA
PHASE II STUDY OF VACCINE FOR ADVANCED PROSTATE CANCER$0
M01 · FY2000 · RR